Global Estrogen Receptor Modulators Market, By Drugs (Raloxifene, Tamoxifen, Ospemifene, Others), Indication (Breast Cancer, Vaginitis, Osteoporosis, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Estrogen Receptor Modulators Market Analysis and Size
The global estrogen receptor modulators market is expected to witness significant growth during the forecast period. Estrogen receptor agonist is being launched and researched to enable estrogen receptor response and study its clinical applications in numerous life-threatening diseases such as cancer and cardiovascular diseases (CVDs). Rising investment in R&D for drug discovery and development and rising healthcare expenditure is expected to improve the revenue of estrogen receptor modulators market in next five years. The rising global burden of patients diagnosed with cancer and tumors is likely to boost the market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global estrogen receptor modulators market in the forecast period 2022-2029. The expected CAGR of global estrogen receptor modulators market is tend to be around 9% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Estrogen receptor modulators are a type of pharmacological agent that blocks the estrogen's function in the tissues by binding to estrogen receptors located at numerous tissues. It is either act as agonists or antagonists in diverse tissues and is widely used in the treatment of breast cancer and post-menopausal osteoporosis.It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Estrogen Receptor Modulators Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Raloxifene, Tamoxifen, Ospemifene, Others), Indication (Breast Cancer, Vaginitis, Osteoporosis, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Alkem Labs Ltd (India), Apotex Inc (Canada), Kyowa Kirin Co., Ltd. (Tokyo)
|
|
Market Opportunities
|
|
Global Estrogen Receptor Modulators Market Dynamics
Drivers
- Increase in Cancer Cases
The rise in cancer cases globally boosts the global estrogen receptor modulators market in the forecast period. As per the WHO report, cancer is the major cause of mortality worldwide and estimated that approximately 9.6 million deaths in 2018. Moreover, it is projected that 627,000 women died from breast cancer, around 15% of all cancer deaths among women across the globe. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs are expected to boost the market growth. The segment is expected to boost the global market as most of the products are available in capsule form and tablet form and it is a very feasible route of administration.
- Growing Osteoporosis Cases
It is projected that over 200 million people globally suffer from this disease. Approximately 30% of all postmenopausal women have osteoporosis in the U.S. and in Europe. As per the National Institute of Health, around 53 million individuals in U.S. either suffer from osteoporosis or at an higher risk because of low bone mass. This boosts the market growth.
Opportunities
- Patent Expiration Encourages New Launches
The patent expiration of old companies can create better opportunities for the new market players. The adoption of combination therapies is a significant factor that contributes to the growth of the capecitabine market. Further, R&D fundings are an add-on to the market.
- Increasing Cases of Asthma
As per the Asthma and Allergy Foundation of America, currently, around 6.2 million children between the age group of 18 years and younger are suffering from asthma in the U.S. It was found that in 2017, 1 in every 12 children had asthma. This creates opportunity for the market growth.
- Rising Healthcare Awareness
Awareness among patients as well as healthcare providers about the incidence of types of cancer is on the rise. Patients and doctors are now more actively participating in learning about the therapies that are available for the treatment of these severe diseases. This is one of the most important drivers in the market. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global estrogen receptor modulators market over a forecast period.
- Increasing Cost Of Treatments
The huge expenditure required for the treatment methods hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.
This global estrogen receptor modulators market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global estrogen receptor modulators market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Estrogen Receptor Modulators Market Scope
The global estrogen receptor modulators market is segmented on the basis of indication, drug, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Breast Cancer
- Vaginitis
- Osteoporosis
- Others
Drug
- Raloxifene
- Tamoxifen
- Ospemifene
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Estrogen Receptor Modulators Market Regional Analysis/Insights
The global estrogen receptor modulators market is analysed and market size insights and trends are provided by indication, drug, distribution channel and end-user as referenced above.
The major countries covered in the global estrogen receptor modulators market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to the increase government initiatives and rapidly aging population.
North America dominates the market due to the rise cases of breast cancer and increase prevalence of osteoporosis as well as advanced healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Estrogen Receptor Modulators Market Share Analysis
The global estrogen receptor modulators market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global estrogen receptor modulators market.
Key players operating in the global estrogen receptor modulators market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Alkem Labs Ltd (India)
- Apotex Inc (Canada)
- Kyowa Kirin Co., Ltd. (Tokyo)
SKU-